| NCT ID | NCT04929899 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Hospital for Sick Children |
| Condition | Acute Lymphoblastic Leukemia (ALL) |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2022-03-01 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.
Eligibility Criteria
Inclusion Criteria: * Age: ≥ 4 years (PeNAT validated in patients 4 to 18 yrs) * newly diagnosed or recurrent disease: first diagnosis of ALL (i.e. non-relapsed) in maintenance therapy * English, French or Spanish-speaking with an English, French or Spanish-speaking guardian (PeNAT available in these languages) * without physical or cognitive impairments that preclude use of the PeNAT * planned to receive PO 6-mercaptopurine * not planned to receive IV, IM, SC or IT chemotherapy or oral or IV corticosteroids during the 7-day study period
Contact & Investigator
Lee Dupuis, PhD
PRINCIPAL INVESTIGATOR
SickKids Research Institute
Frequently Asked Questions
Who can join the NCT04929899 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 18 Years, studying Acute Lymphoblastic Leukemia (ALL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04929899 currently recruiting?
Yes, NCT04929899 is actively recruiting participants. Contact the research team at lee.dupuis@sickkids.ca for enrollment information.
Where is the NCT04929899 trial being conducted?
This trial is being conducted at Los Angeles, United States, New Brunswick, United States, Falls Church, United States, Toronto, Canada.
Who is sponsoring the NCT04929899 clinical trial?
NCT04929899 is sponsored by The Hospital for Sick Children. The principal investigator is Lee Dupuis, PhD at SickKids Research Institute. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.